American Medical Systems’ New MoXy® Fiber Delivers Over 50 Percent More Energy
MINNETONKA, Minn., Aug. 21, 2012 /PRNewswire/ — American Medical Systems (AMS), an Endo Health Solutions (Nasdaq: ENDP) company and a leading provider of devices and therapies for male and female pelvic health, today introduced the new 650kJ MoXy(®) fiber for its class-leading GreenLight XPS(®) system for photoselective vaporization of the prostate. Providing more than 50 percent more energy than the previous fiber for the same price, the new MoXy fiber will enable physicians to treat larger glands with a single fiber, offering improved overall value and greater cost efficiency.
“The GreenLight(TM) system continues to be the leading laser surgical treatment for BPH (benign prostatic hyperplasia),” said Joe Martin, senior vice president and general manager for BPH Therapy at AMS. “In response to the changing clinical and economic needs of our customers, we’ve developed this innovative enhancement to our MoXy fiber that will treat the majority of gland sizes with the GreenLight system, extending the utility of the procedure.”
The higher energy fiber will enable physicians to treat larger glands. The 650kJ MoXy fiber offers the same safety, reliability, and product specifications as the original 400kJ model, and patients with large glands may benefit from more complete removal of tissue.
“As a busy practicing urologist, I’m pleased to begin utilizing the new MoXy fiber, which will offer a longer-lasting and more cost-effective advanced laser fiber to treat BPH,” said Dr. Mahmood Hai, President, Affiliates Division, Comprehensive Urology and Executive Director, The Surgical Institute of Michigan. “This innovation will allow us to treat a broader range of patients, especially those with larger prostates as they are becoming more common. It greatly adds to the already improved overall value of the GreenLight laser in the treatment of prostatic diseases.”
With more than 500,000 procedures performed worldwide, the AMS GreenLight Laser Therapy system is delivering the effectiveness of transurethral resection of the prostate (TURP) with lower morbidity, fewer complications, and shorter hospital stays. The treatment is durable and suitable for most patients with enlarged prostates, delivering rapid urine flow improvement( )and long-lasting symptom relief.
About American Medical Systems
American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one’s quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems’ products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The Company’s products were used to treat approximately 340,000 patients in 2010. AMS is part of Endo Health Solutions Inc. (Nasdaq: ENDP), a diversified healthcare company that is dedicated to improving care through a combination of branded products, generics, devices, technology and services. (http://www.endo.com)
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in Endo Health Solutions’ Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in the Endo Health Solutions Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE Endo Health Solutions